Taiga Nishihori Selected Research

Myelodysplastic Syndromes (Myelodysplastic Syndrome)

10/2022	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
3/2022	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
11/2021	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
11/2021	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
1/2021	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
1/2021	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
1/2021	Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
11/2020	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
10/2020	Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
1/2020	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taiga Nishihori Research Topics

Disease

42	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2024 - 02/2011
37	Multiple Myeloma 12/2023 - 10/2011
35	Neoplasms (Cancer) 12/2023 - 11/2002
19	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2022 - 06/2014
17	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 10/2010
14	Lymphoma (Lymphomas) 01/2023 - 09/2013
12	Infections 12/2023 - 09/2013
12	Leukemia 10/2022 - 06/2015
11	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023 - 01/2020
10	Hematologic Neoplasms (Hematological Malignancy) 11/2023 - 01/2017
8	Cytokine Release Syndrome 11/2023 - 01/2020
8	Bronchiolitis Obliterans Syndrome 11/2022 - 10/2010
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 03/2016
6	Plasma Cell Leukemia 01/2023 - 12/2011
4	Cytopenia 02/2024 - 09/2013
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2024 - 11/2014
4	Primary Myelofibrosis (Myelosclerosis) 07/2023 - 11/2010
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2020 - 01/2016
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 05/2024 - 10/2015
3	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2023 - 10/2015
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2021 - 10/2015
3	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 10/2015
3	Pathologic Complete Response 01/2020 - 03/2016
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 01/2018
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 06/2015
2	Residual Neoplasm 02/2024 - 04/2016
2	Renal Insufficiency (Renal Failure) 08/2023 - 09/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2023 - 01/2023
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 05/2017
2	Amyloidosis 01/2022 - 11/2015
2	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2022
2	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2022 - 01/2018
2	Cytomegalovirus Infections (Inclusion Disease) 10/2021 - 01/2015
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 01/2020
2	Thrombotic Microangiopathies 01/2020 - 09/2011
1	Critical Illness (Critically Ill) 08/2023
1	Inflammation (Inflammations) 04/2023

Drug/Important Bio-Agent (IBA)

16	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 10/2015
13	Tacrolimus (Prograf)FDA LinkGeneric 01/2024 - 12/2012
12	Chimeric Antigen ReceptorsIBA 01/2024 - 01/2021
11	Melphalan (Alkeran)FDA LinkGeneric 07/2023 - 06/2012
9	Busulfan (Busulfex)FDA Link 07/2023 - 10/2010
8	fludarabineIBA 07/2023 - 02/2011
8	axicabtagene ciloleucelIBA 01/2023 - 01/2020
8	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 12/2012
7	Bortezomib (Velcade)FDA Link 01/2023 - 06/2012
7	Lenalidomide (CC 5013)FDA Link 01/2023 - 09/2013
7	Calcineurin InhibitorsIBA 01/2021 - 09/2011
6	Sirolimus (Rapamycin)FDA Link 11/2023 - 09/2011
6	GlucocorticoidsIBA 11/2022 - 10/2010
6	Rituximab (Mabthera)FDA Link 01/2020 - 02/2011
5	AntigensIBA 11/2023 - 09/2013
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2014
4	Mycophenolic Acid (Cellcept)FDA LinkGeneric 11/2023 - 01/2019
4	idecabtagene vicleucelIBA 10/2023 - 12/2022
3	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2023 - 01/2023
3	Interleukin-6 (Interleukin 6)IBA 11/2023 - 01/2021
3	SteroidsIBA 01/2021 - 11/2014
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 01/2016
3	Alemtuzumab (Campath)FDA Link 01/2020 - 09/2013
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019 - 10/2015
2	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2023
2	VaccinesIBA 11/2023 - 09/2013
2	Ferritins (Ferritin)IBA 10/2023 - 01/2021
2	B-Cell Maturation AntigenIBA 09/2023 - 01/2023
2	LigandsIBA 01/2023 - 01/2021
2	tocilizumab (atlizumab)FDA Link 01/2023 - 01/2021
2	tisagenlecleucelIBA 01/2023 - 01/2021
2	Proteasome InhibitorsIBA 01/2023 - 10/2015
2	ofatumumab FDA Link 11/2022 - 06/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2021
2	InterferonsIBA 01/2021 - 10/2005
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 10/2015
2	liposomal doxorubicin (Doxil)FDA Link 11/2015 - 01/2014
2	Glucose (Dextrose)FDA LinkGeneric 09/2015 - 02/2011
1	venetoclaxIBA 02/2024
1	AlbuminsIBA 12/2023
1	SurvivinIBA 11/2023
1	Protein Isoforms (Isoforms)IBA 11/2023
1	pembrolizumabIBA 11/2023
1	C-Reactive ProteinIBA 10/2023
1	CytokinesIBA 04/2023
1	Biomarkers (Surrogate Marker)IBA 04/2023
1	CreatinineIBA 04/2023
1	Troponin IIBA 04/2023
1	Interleukin-15 (Interleukin 15)IBA 04/2023

Therapy/Procedure

106	Cell Transplantation 05/2024 - 10/2010
56	Therapeutics 01/2024 - 10/2005
31	Transplantation 11/2023 - 02/2011
17	Homologous Transplantation 01/2023 - 10/2010
16	Hematopoietic Stem Cell Transplantation 01/2023 - 11/2011
12	Drug Therapy (Chemotherapy) 11/2023 - 09/2015
12	Autologous Transplantation 01/2023 - 09/2013
6	Stem Cell Transplantation 01/2023 - 01/2019
4	Immunotherapy 04/2023 - 09/2013
2	Critical Care (Surgical Intensive Care) 12/2023 - 08/2023
2	Artificial Respiration (Mechanical Ventilation) 01/2023 - 10/2022
2	Photopheresis 10/2017 - 11/2014
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 11/2023